Proactive - Interviews for investors

Touchstone Exploration CEO Paul Baay shared an optimistic update about the company's recent activities, particularly highlighting the positive results from the drilling at the Cascadura-2 well and broader operational advancements.

The well, initially aimed to reach 8,300 feet, was concluded at 7,132 feet due to encountering thick gas-charged sands earlier than expected. This outcome aligns with the company's strategy and signifies the commencement of a new growth phase, leveraging the infrastructure such as facilities and pipelines they have developed over the past years.

Baay said the significance of these results lies not just in the immediate production potential but also in the confirmation of gas presence east of the original discovery, indicating an extended area for further exploration and development. This finding is pivotal for Touchstone's growth, suggesting a promising future with more wells planned for development between the newfound points and further explorations to the east and north.

In addition to the Cascadura-2 well, Baay mentioned efforts to optimize production at existing sites, including the Cascadura-1 and CO-1 blocks. These optimizations involve perforating additional sections in wells to enhance production rates, a process they are carefully managing to ensure stable and reliable data before public reporting. This approach of cautious optimization and strategic drilling, including moving rigs to new locations for further exploration, points towards a holistic strategy aimed at maximizing resource extraction efficiently and sustainably.

#TouchstoneExploration #OilAndGas #DrillingResults #CascaduraWell #EnergySector #NaturalGas #OilAndGasIndustry #ExplorationAndProduction #OperationalUpdate #EnergyInvestment #GasProduction #OilDrilling #EnergyInnovation #SustainableEnergy #EnergyDevelopment #ResourceOptimization #EnergyEconomics #EnergyFuture #InvestorUpdate #EnergyGrowth #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Alpha Financial Markets Consulting PLC CEO Luc Baqué and chief financial officer John Paton join Proactive's Stephen Gunnion with details of the company's current performance and future outlook.

Amid a competitive global consulting market, Baqué told Proactive that Alpha anticipates a net free income growth of up to 5% for the fiscal year ending March 31, 2024, with improved margins from the first half and utilization levels nearing targets in the second half, albeit recovering slower than expected. The company enters the fourth quarter with a strong pipeline, signaling an optimistic sales trend and utilization close to desired levels.

Regionally, Paton said North America has shown resilience, with utilization levels bouncing back strongly, contributing significantly as a key strategic market. The UK faces more competitive challenges, with utilization not yet at target levels, but still entering the final quarter with a promising pipeline. Europe, particularly in the French insurance sector, and the APAC region are also performing well, with the latter setting a new record pipeline, positioning Alpha for a strong start to the new financial year.

Looking forward, Alpha expects the current market challenges to be short-term, forecasting incremental growth, improved utilization, and margins through FY25. With a strong pipeline, recent sales wins, and a robust balance sheet, Alpha is confident in its medium to long-term growth prospects, aligning with its ambition to double the business by 2028.

‌

#AlphaFinancialMarkets #FinancialConsulting #MarketInsights #GlobalConsulting #FinancialGrowth #BusinessOutlook #InvestmentConsulting #ManagementConsulting #TechnologyConsulting #StrategicGrowth #CorporateFinance #FinancialServices #ProfessionalServices #BusinessStrategy #EconomicOutlook #FutureGrowth #FinancialYear2024 #BusinessAmbition #FinancialAnalysis #ConsultingIndustry #AlphaFMC #LucBaque #JohnPaton #ProactiveLondon #FinancialForecasting #MarketDynamics #BusinessPipeline #FinancialPerformance #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Creo Medical Group CEO Craig Gulliford joined Proactive's Stephen Gunnion following the deployment of the Speedboat UltraSlim device in the Asia Pacific region, marking a significant milestone for the company.

The Speedboat UltraSlim, a culmination of years of development, miniaturizes laparoscopic advanced energy capabilities into a compact device enhancing endoscopic surgery. This innovation enables precise surgical procedures with minimal invasiveness, targeting precancerous and cancerous lesions in the gastrointestinal tract.

Gulliford highlighted the device's successful clinical applications in various regions, including the US, South America, Europe, and recently at the Prince of Wales Hospital in Hong Kong, focusing on stomach and colon lesions. The technology aims to reduce the need for conventional surgery, offering a safer alternative with lower complication rates.

Additionally, Creo announced a strategic collaboration with Khalifa University of Science and Technology in Abu Dhabi to develop intellectual property and expand its technological reach into the Middle East. This partnership aims to foster innovation and enhance medical outcomes, reinforcing Creo Medical's commitment to advancing medical technology and improving patient care globally.

‌

#CreoMedicalGroup #SpeedboatInjectUltra #MedicalInnovation #EndoscopicSurgery #LaparoscopicSurgery #AsiaPacificHealthcare #MedicalDevices #GastrointestinalHealth #PrecancerousLesionsTreatment #HealthcareTechnology #CraigGulliford #MedicalResearch #KhalifaUniversity #MedicalCollaboration #GlobalHealthcare #SurgicalDevices #Endoscopy #MinimallyInvasiveSurgery #MedicalIndustryInterview #ProactiveLondon #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Inc Chief Scientific Officer Hella Kohlhof sheds light on her crucial role and the groundbreaking strides being made in the scientific world ahead of the International Day of Women and Girls in Science on 11 February.

As CSO, Kohlhof is pivotal in crafting the scientific strategy for Immunic's projects, focusing on understanding molecular actions, ensuring safety in preclinical regulatory work, and developing biomarkers for early activity indications. Her responsibilities extend beyond internal operations to engaging with stakeholders, including investors and scientists, highlighting the collaborative essence of scientific progress.

Kohlhof told Proactive her passion for science was ignited in her school days, fascinated by the intricate mechanisms of viruses. This curiosity led her from working as a lab technician to pursuing advanced studies in biology, culminating in a PhD focused on viral behavior. Her journey wasn't without challenges; she recalls a noteworthy incident underscoring the gender biases in science, which taught her the importance of resilience and not taking gendered assumptions personally.

For young women aspiring to careers in science, Kohlhof emphasizes the power of curiosity and the willingness to seize opportunities, even in the face of uncertainty. She advocates for a fearless approach to learning and exploration, underscoring that achievements in science come from a blend of passion and perseverance.

#ImmunicInc #WomenInScience #ScientificInnovation #HellaKohlhof #Biotech #ScienceCareers #FemaleScientists #MolecularBiology #PreclinicalResearch #ScienceEducation #STEM #PhDinBiology #Virology #ScientificResearch #InternationalDayOfWomenAndGirlsInScience #CareerAdvice #WomenInSTEM #Biotechnology #ScientificStrategy #RegulatoryWork #Biomarkers #QualityManagement#proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive journalist William "Billy" Farrington provides a comprehensive overview of the current cryptocurrency market, highlighting a significant bullish trend in Bitcoin prices.

This week, Bitcoin saw a remarkable rally, reaching around $47,000, marking a 10% increase week on week. This surge is particularly notable as it comes in the wake of Exchange Traded Funds (ETFs) from major financial institutions like BlackRock and Fidelity being approved, a move initially expected to catalyze a bullish momentum for Bitcoin. Despite a slow start post-ETF approvals, the market is now witnessing the positive impact of these developments, with substantial cash inflows into the spot market, particularly highlighted by a $1.8 billion net cash inflow across ten ETF products.

Farrington also sheds light on preparations for the upcoming Bitcoin halving in April, an event anticipated to further fuel the market's bullishness. Hive Digital, for instance, is bolstering its mining capabilities with the acquisition of 7,000 new ASIC computers, aiming to mine Bitcoin at a cost of $10,000 per unit, significantly below the current market price.

Additionally, Farrington touches on the intriguing legal battle involving Craig Wright, who claims to be Satoshi Nakamoto, Bitcoin's pseudonymous creator. Wright is currently facing a lawsuit from the Crypto Open Patent Alliance, seeking to challenge his claim to the Bitcoin invention in the UK High Court.

#CryptoRoundUp #BitcoinRally #ETFApprovals #BitcoinHalving #CraigWright #SatoshiNakamoto #BitcoinMining #CryptoMarketUpdate #BillyFarrington #DigitalCurrencies #BitcoinPriceAction #CryptoInsights #BlockchainTechnology #CryptocurrencyNews #BitcoinETF #HiveDigital #ASICMiners #BitcoinInvestment #CryptoLegalBattle #BitcoinScarcity #ProactiveJournalist #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Elutia CEO Randy Mills joined Steve Darling from Proactive to discuss the company's groundbreaking product, CanGarooRM, a drug-eluting biologic designed to safeguard implanted medical devices such as pacemakers. Founded by Mills and Kevin Regan, both esteemed veterans in the biotech industry, Elutia aims to revolutionize healthcare by combining regenerative medicine with localized drug delivery.

During the interview, Mills shed light on CanGarooRM's unique formulation, which includes antibiotics to prevent infections and device migration, ultimately enhancing patient safety. With the FDA accepting their filing in December, Elutia is optimistic about receiving favorable results in the second quarter of this year. If approved, CanGarooRM has the potential to capture a significant share of the market, estimated to exceed $500 million.

Mills further elaborated that Elutia has completed product development and is poised to commence commercial production by the late second quarter. A soft launch is planned for the third quarter, followed by full-scale deployment by the fourth quarter of this year. This strategic timeline positions Elutia for substantial growth pending regulatory approval, with CanGarooRM poised to address critical needs in the healthcare industry and improve patient outcomes.

In summary, the interview underscored Elutia's promising trajectory and the transformative potential of CanGarooRM in enhancing medical device safety. With a strong foundation in regenerative medicine and localized drug delivery, Elutia is poised to make a significant impact in healthcare innovation, driving positive change and improving patient care globally. Stay tuned for further updates as Elutia progresses towards regulatory approval and commercialization of CanGarooRM.

#proactiveinvestors #elutiainc #nasdaq #elut

#biotech #regenerativemedicine #medicaldevices #FDAapproval #healthtech #innovation #biologicalimplants #drugdelivery #pacemakers #antibiotics #medicaltechnology #healthcare #startup #CEOinterview #medicalinnovation #biomedical #implantabledevices #FDAreview #medicalresearch #biotechindustry #medicaldeviceindustry #healthcareindustry #FDAapprovalprocess #medicaldeviceapproval#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hive Digital Technologies Executive Chairman Frank Holmes joined Steve Darling from Proactive to disclose the unaudited production figures from the company's global Bitcoin operations for the month of January. Impressively, Hive Digital Technologies produced 234.6 Bitcoin during that period, reflecting the company's robust mining capabilities.

Holmes elaborated that the company maintained over 3.88 Exahash of Bitcoin mining capacity on average for January 2024, which includes both ASIC and GPU BTC hashrate. Additionally, Hive Digital Technologies bolstered its HODL position, ending January with 1,939 BTC, marking a notable 14% increase from the previous month.

During the interview, Holmes emphasized the company's average daily production rate of 7.6 BTC in January, underscoring its consistent mining performance. Moreover, Hive Digital Technologies has undertaken significant upgrades to its fleet of ASICs to enhance global fleet efficiency and reduce the average production cost per Bitcoin.

Holmes highlighted the acquisition of Bitmain S21 Antminers as a key initiative to optimize mining operations. These state-of-the-art machines are renowned for their efficiency and can produce a Bitcoin at a cost of approximately $10,000, assuming a power price of $0.04 per KWHR. Hive Digital Technologies has procured 7,000 of these cutting-edge machines, positioning the company for continued success and profitability in the competitive Bitcoin mining landscape.

In summary, Holmes conveyed Hive Digital Technologies' strong performance in Bitcoin production for January, underpinned by its strategic investments in mining equipment and operational enhancements. With a commitment to efficiency and innovation, Hive Digital Technologies remains at the forefront of the cryptocurrency mining industry, poised to capitalize on the evolving dynamics of the digital asset ecosystem.

#proactiveinvestors #hivedigitaltechnologies #tsxv #hive #nasdaq #hive #bitcoin #

#HIVE #cryptocurrency #Bitcoin #mining #technology #sustainability #renewableenergy #CEO #investment #digitalassets #crypto #finance #blockchain #revenuegrowth #digitaltransformation #innovation #greenenergy #videotech #computing #CEOconfidence #financialnews #cryptoindustry #BTC #ETH #FrankHolmes#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

U.S. Global Investors CEO Frank Holmes joined Steve Darling from Proactive to delve into the significant gold purchases observed in China. Holmes attributes these purchases to concerns over currency stability, particularly amid troubles in the real estate market. As China's real estate investments face challenges, both citizens and the government are turning to gold as a safe haven, seeking to safeguard their wealth amidst economic uncertainties.

During the discussion, Holmes underscored gold's consistent performance, noting its outperformance of the S&P by a ratio of two-to-one this century. Against the backdrop of modern monetary theory, gold continues to shine as an attractive asset, offering stability and value preservation in volatile markets.

Turning his attention to gold mining operations, Holmes dismissed South Africa due to operational challenges but identified North America as a promising hub for gold exploration and production. With an increasing focus on strategic minerals, North America presents lucrative opportunities for investors and mining companies alike.

Holmes further highlighted the bullish trend for gold amid global elections and falling interest rates, signaling positive prospects for North American gold ventures. As a safe haven amid escalating global uncertainties, the gold sector in North America holds increasing value, offering investors a refuge in turbulent times.

In summary, Holmes painted a compelling picture of the gold market, emphasizing its resilience and attractiveness as a hedge against economic instability. With China's gold purchases reflecting broader concerns over currency stability and North America emerging as a key player in gold exploration and production, investors stand to benefit from the continued strength of the gold sector amidst evolving global dynamics.

#proactiveinvestors #usglobalinvestors #airline #travel #oil #jets

#GoldInvesting, #USGlobalInvestors, #ChineseNewYear, #GoldMarket, #CurrencyStability, #SafeHaven, #RealEstateCrisis, #ModernMonetaryTheory, #NorthAmericanGold, #StrategicMinerals, #GlobalEconomy, #ElectionYear, #InterestRates, #InvestmentStrategy, #MarketAnalysis, #MiningIndustry, #PreciousMetals, #EconomicOutlook, #FinancialNews, #InvestmentOpportunities, #GoldPrices, #AssetAllocation, #MarketTrends, #CEOInterview#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team. CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward.

Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed.

Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024. Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB.

Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study. These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options.

The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases. With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare.

#proactiveinvestors #cervomedinc #nasdaq

#neurodegenerative #dementia #LewyBodies #clinicaltrial #neflamapimod #biopharmaceutical #JoshuaBoger #drugdevelopment #brainhealth #healthcare #innovation #leadership #AlkeusPharmaceuticals #DLB #neuroscience #p38MAPkinase #AscenDLB #treatmentoptions #clinicalresearch #neurologicalhealth #patientcare #caregivers #medicalscience #researchanddevelopment

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Simply Solventless Concentrates CEO Jeff Swainson joins Steve Darling from Proactive to share exciting updates regarding the company's upcoming activities. Simply Solventless Concentrates anticipates a busy month ahead, with approximately $1.25 million in purchase orders lined up from Alberta and Ontario. Additionally, the company is set to launch six third-party branded products in Alberta and one in Ontario, further expanding its market presence.

During the interview, Swainson underscored the importance of strategic leadership in supporting the company's growth trajectory. To this end, Simply Solventless Concentrates announced the appointment of Jeff Lawrence to the position of Vice President, Marketing & Sales. Lawrence brings over 30 years of experience in industrial and consumer packaged goods, including five years in the cannabis industry. With a proven track record of driving sales growth and propelling startups through strategic development, team building, and effective leadership, Lawrence is poised to make a significant impact on the company's sales and marketing initiatives.

Swainson highlighted Lawrence's previous role as National Director of Sales at Dycar Pharmaceuticals, where he played a key role in overseeing the launch of four brands and scaling store listings from 70 to over 2,200 across five provinces. Lawrence's extensive experience and leadership acumen make him a valuable addition to the Simply Solventless Concentrates team, positioning the company for continued success and expansion in the competitive cannabis market.

With a robust pipeline of purchase orders and new product launches on the horizon, Simply Solventless Concentrates is primed for growth under Lawrence's leadership. Stay tuned for further updates as the company continues to execute its strategic initiatives and capitalize on emerging opportunities in the cannabis industry.

#proactiveinvestors #simplysolventlessconcentrates #tsxv #hash

#Concentrates #CannabisIndustry #CBD #THC #ProductLaunch #BusinessGrowth #CEOInterview #CannabisCommunity #CanadianCannabis #SolventlessExtracts #BrandExpansion #Innovation #Entrepreneurship #FinancialSuccess #MarketTrends #IndustryInsights #ProductDevelopment #StrategicVision #BrandBuilding #CanadianBusiness #Leadership #EntrepreneurLife #CannabisCulture

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews